1. Home
  2. ZYME vs HIPO Comparison

ZYME vs HIPO Comparison

Compare ZYME & HIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZYME
  • HIPO
  • Stock Information
  • Founded
  • ZYME 2003
  • HIPO 2015
  • Country
  • ZYME United States
  • HIPO United States
  • Employees
  • ZYME N/A
  • HIPO N/A
  • Industry
  • ZYME Biotechnology: Pharmaceutical Preparations
  • HIPO Property-Casualty Insurers
  • Sector
  • ZYME Health Care
  • HIPO Finance
  • Exchange
  • ZYME Nasdaq
  • HIPO Nasdaq
  • Market Cap
  • ZYME 968.5M
  • HIPO 842.4M
  • IPO Year
  • ZYME 2017
  • HIPO N/A
  • Fundamental
  • Price
  • ZYME $14.81
  • HIPO $33.83
  • Analyst Decision
  • ZYME Buy
  • HIPO Strong Buy
  • Analyst Count
  • ZYME 7
  • HIPO 5
  • Target Price
  • ZYME $20.00
  • HIPO $34.40
  • AVG Volume (30 Days)
  • ZYME 453.7K
  • HIPO 185.9K
  • Earning Date
  • ZYME 08-07-2025
  • HIPO 08-06-2025
  • Dividend Yield
  • ZYME N/A
  • HIPO N/A
  • EPS Growth
  • ZYME N/A
  • HIPO N/A
  • EPS
  • ZYME N/A
  • HIPO N/A
  • Revenue
  • ZYME $122,867,000.00
  • HIPO $425,000,000.00
  • Revenue This Year
  • ZYME $107.76
  • HIPO $27.97
  • Revenue Next Year
  • ZYME $2.35
  • HIPO $25.47
  • P/E Ratio
  • ZYME N/A
  • HIPO N/A
  • Revenue Growth
  • ZYME 95.94
  • HIPO 43.15
  • 52 Week Low
  • ZYME $9.03
  • HIPO $15.74
  • 52 Week High
  • ZYME $17.70
  • HIPO $35.44
  • Technical
  • Relative Strength Index (RSI)
  • ZYME 62.78
  • HIPO 68.00
  • Support Level
  • ZYME $13.48
  • HIPO $30.65
  • Resistance Level
  • ZYME $15.35
  • HIPO $34.08
  • Average True Range (ATR)
  • ZYME 0.58
  • HIPO 1.10
  • MACD
  • ZYME 0.10
  • HIPO 0.20
  • Stochastic Oscillator
  • ZYME 80.21
  • HIPO 95.49

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

About HIPO Hippo Holdings Inc.

Hippo Holdings Inc is a home insurance group that created a new standard of care and protection for homeowners. It provides insurance for computers, home offices, electronics, appliances, water backup, and service line coverage, among others. It has three reportable segments Services segment earns fees and commission income without assuming underwriting risk or need for reinsurance, Insurance-as-a-Service managed through the company's subsidiary Spinnaker is a platform to support third-party MGAs, and the Hippo Home Insurance Program engaged in homeowners insurance business. It generates the majority of its revenue from the Insurance-as-a-Service segment.

Share on Social Networks: